Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Investigational New Drugs"
DOI: 10.1007/s10637-020-01023-z
Abstract: Purpose Axitinib is an orally active multikinase inhibitor currently used to treat patients with metastatic renal cell carcinoma (RCC). This study examined the pharmacokinetics of axitinib and the relationship between peak drug concentration (C max… read more here.
Keywords: renal cell; orally active; cell carcinoma; metastatic renal ... See more keywords